# Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Source: https://onco.cc/trials/nct00199043/  
OnCo record `nct00199043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rasburicase in Leukaemia, run by Goethe University, completed.

## Summary

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma is a phase 3 interventional study registered as NCT00199043 by Goethe University, with 80 participants recorded, started 2003-05 and reaching its primary completion in 2008-05. Interventions recorded: Allopurinol, Rasburicase. Conditions recorded: Adult Acute Lymphocytic Leukemia, High-grade Lymphoma.

Linked to the drug Rasburicase because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00199043
- Phase: 3
- Setting: Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs)
- Sponsor: Goethe University
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT00199043: https://clinicaltrials.gov/study/NCT00199043

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Rasburicase](https://onco.cc/drugs/rasburicase/)

---
JSON: https://onco.cc/api/v1/entities/nct00199043.json